SAN DIEGO, Aug. 2, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced it will report its second quarter 2017
financial results and business progress on Wednesday, August
9, 2017, after the close of the U.S. financial markets.
To receive Tocagen's press releases and other investor
information, please visit the Investor Relations page of the
company's website and register for email alerts.
About Tocagen
Tocagen is a clinical-stage,
cancer-selective gene therapy company developing first-in-class,
broadly applicable product candidates designed to activate a
patient's immune system against their own cancer. Tocagen is
developing its lead investigational product candidate, Toca 511
& Toca FC, initially for the treatment of recurrent high grade
glioma (HGG), a disease with significant unmet medical need. The
U.S. Food and Drug Administration (FDA) has granted Toca 511 &
Toca FC Breakthrough Therapy Designation for the treatment of
recurrent HGG and the European Medicines Agency (EMA) has granted
Toca 511 PRIME (PRIority MEdicines) designation for the treatment
of HGG. Tocagen has received grant support from leading brain
cancer foundations, including Accelerate Brain Cancer Cure (ABC2),
National Brain Tumor Society (NBTS), American Brain Tumor
Association (ABTA), Musella Foundation and Voices Against Brain
Cancer (VABC).
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-second-quarter-2017-financial-results-on-wednesday-august-9-300498658.html
SOURCE Tocagen Inc.